Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients.

Zachary A Yetmar Elena BeamJohn C O'HoroRavindra GaneshDennis M BierleLisa M BrumbleMaria Teresa SevilleRaymund R Razonable

Published in: Open forum infectious diseases (2021)

Monoclonal antibody treatment has favorable outcomes with minimal adverse effects in solid organ transplant recipients with mild to moderate COVID-19. Earlier administration of monoclonal antibody therapy appears to be more efficacious.

Keyphrases

monoclonal antibody
coronavirus disease
sars cov
respiratory syndrome coronavirus
stem cells
type diabetes
mesenchymal stem cells
combination therapy
skeletal muscle